Hierarchical assembly of hyaluronan coated albumin nanoparticles for pancreatic cancer chemoimmunotherapy

Nanoscale ◽  
2019 ◽  
Vol 11 (35) ◽  
pp. 16476-16487 ◽  
Author(s):  
Ying Hu ◽  
Xue Chen ◽  
Yingying Xu ◽  
Xianru Han ◽  
Mou Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Effective Treatment ◽  
Patient Survival ◽  
Treatment Options ◽  
Hierarchical Assembly ◽  
Albumin Nanoparticles ◽  
Poor Patient ◽  
Patient Survival Rate ◽  
Poor Patient Survival

Pancreatic cancer is a highly malignant carcinoma with limited effective treatment options, resulting in a poor patient survival rate of less than 5%.

scholarly journals Role of the Immune System Elements in Pulmonary Arterial Hypertension

2021 ◽  
Vol 10 (16) ◽  
pp. 3757
Author(s):  
Michał Tomaszewski ◽  
Dominika Bębnowska ◽  
Rafał Hrynkiewicz ◽  
Jakub Dworzyński ◽  
Paulina Niedźwiedzka-Rystwej ◽  
...  
Keyword(s):  
Immune System ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Immune Cells ◽  
Patient Survival ◽  
Poor Patient ◽  
Pulmonary Arterial ◽  
Patient Survival Rate ◽  
Poor Patient Survival

Pulmonary arterial hypertension (PAH) is a relatively rare disease, but, today, its incidence tends to increase. The severe course of the disease and poor patient survival rate make PAH a major diagnostic and therapeutic challenge. For this reason, a thorough understanding of the pathogenesis of the disease is essential to facilitate the development of more effective therapeutic targets. Research shows that the development of PAH is characterized by a number of abnormalities within the immune system that greatly affect the progression of the disease. In this review, we present key data on the regulated function of immune cells, released cytokines and immunoregulatory molecules in the development of PAH, to help improve diagnosis and targeted immunotherapy.

scholarly journals Overexpression of Semaphorin-3E enhances pancreatic cancer cell growth and associates with poor patient survival

Oncotarget ◽  
2016 ◽  
Vol 7 (52) ◽  
pp. 87431-87448 ◽  
Author(s):  
Lin-Kin Yong ◽  
Syeling Lai ◽  
Zhengdong Liang ◽  
Ethan Poteet ◽  
Fengju Chen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Pancreatic Cancer Cell ◽  
Patient Survival ◽  
Cancer Cell Growth ◽  
Poor Patient ◽  
Poor Patient Survival

scholarly journals Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Fei Sun ◽  
Wen Ding ◽  
Jie-Hua He ◽  
Xiao-Jing Wang ◽  
Ze-Biao Ma ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Patient Survival ◽  
Poor Patient ◽  
Poor Patient Survival

scholarly journals Elevated expression of SATB1 is involved in pancreatic tumorigenesis and is associated with poor patient survival

2017 ◽  
Vol 16 (6) ◽  
pp. 8842-8848 ◽  
Author(s):  
Lei Guo ◽  
Jianjiang Zheng ◽  
Tao Yu ◽  
Yuequan Liu ◽  
Lukun Duo
Keyword(s):  
Patient Survival ◽  
Poor Patient ◽  
Elevated Expression ◽  
Poor Patient Survival

Renal transplantation in the first year of life: the treatment of choice for infants with end-stage renal disease.

1992 ◽  
Vol 2 (12) ◽  
pp. S228
Author(s):  
J S Najarian ◽  
P S Almond ◽  
M Mauer ◽  
B Chavers ◽  
T Nevins ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Transplantation ◽  
Survival Rate ◽  
Living Donor ◽  
Patient Survival ◽  
First Year ◽  
End Stage Renal Failure ◽  
End Stage ◽  
First Year Of Life ◽  
Patient Survival Rate

The treatment of choice for end-stage renal failure within the first year of life is controversial. Between September 1970 and February 1991, we performed 28 kidney transplants (27 primary, 1 retransplant, 23 living donor, 5 cadaver) in infants less than 1 yr of age (mean, 7 +/- 2 months; range, 6 wk to 12 months). The 1-yr patient survival rate for living donor recipients was 100% versus 20% for cadaver recipients (P = 0.0001). The 1-yr graft survival rate for living donor recipients was 96% versus 20% for cadaver recipients (P = 0.001). The 1-yr patient survival rate for cyclosporin A (CSA) recipients (N = 12) was 100% versus 75% for non-CSA recipients (P = 0.03). The 1-yr graft survival rate for CSA recipients was 92% versus 75% for non-CSA recipients (P = 0.08). There was no difference in the number of rejection episodes or serum creatinine levels in CSA versus non-CSA recipients. Compared with pretransplant values, the mean posttransplant standard deviation scores (SDS) for height (N = 18), weight (N = 22), and head circumference (N = 8) improved: height SDS from -1.9 to -1.5 (not significant); weight SDS from -2.5 to 0.6 (P less than 0.0005); head circumference SDS from -2.0 to -0.7 (P = 0.01). Because no other renal replacement therapy can match these results, we conclude that renal transplantation is the treatment of choice for infants with end-stage renal failure.

Lamins as cancer biomarkers

2010 ◽  
Vol 38 (1) ◽  
pp. 297-300 ◽  
Author(s):  
Clare R. Foster ◽  
Stefan A. Przyborski ◽  
Robert G. Wilson ◽  
Christopher J. Hutchison
Keyword(s):  
Cancer Cells ◽  
Patient Survival ◽  
Cancer Biomarkers ◽  
Tumour Cells ◽  
Diagnostic Biomarkers ◽  
Cancer Subtypes ◽  
Multifunctional Proteins ◽  
Poor Patient ◽  
Poor Patient Survival

Lamins are multifunctional proteins that are often aberrantly expressed or localized in tumours. Here, we endeavour to assess their uses as cancer biomarkers: to diagnose tumours, analyse cancer characteristics and predict patient survival. It appears that the nature of lamin function in cancer is very complex. Lamin expression can be variable between and even within cancer subtypes, which limits their uses as diagnostic biomarkers. Expression of A-type lamins is a marker of differentiated tumour cells and has been shown to be a marker of good or poor patient survival depending on tumour subtype. Further research into the functions of lamins in cancer cells and the mechanisms that determine its patterns of expression may provide more potential uses of lamins as cancer biomarkers.

Sign in / Sign up

Export Citation Format

Share Document